Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | HINT1 | P49773 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 2/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | KRAS | P01116 | 6/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503193 | 1.00 | POLB (0.60) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL22348827 | 0.94 | POLB (0.58) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL22348824 | 0.94 | POLB (0.58) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL23187769 | 0.93 | POLB (0.57) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL22348826 | 0.93 | POLB (0.57) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL21162576 | 0.93 | POLB (0.57) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL29944545 | 0.93 | POLB (0.57) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL22348816 | 0.92 | POLB (0.56) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL22348812 | 0.92 | POLB (0.56) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL23161839 | 0.91 | POLB (0.56) | POLBP2RY2P2RY4P2RY6TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139525-A1 | NUCLEOTIDE PRODRUGS | CERECOR INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210101923-A1 | NUCLEIC ACID PRODRUGS | AVALO THERAPEUTICS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10745435-B2 | Nucleic acid prodrugs | CERECOR, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180346508-A1 | NUCLEIC ACID PRODRUGS | AVALO THERAPEUTICS, INC. | 2018-12-06 | — | — | US | disclosed |
| EP-3377512-A1 | NUCLEIC ACID PRODRUGS | Ichorion Therapeutics, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139525-A1 | NUCLEOTIDE PRODRUGS | FPGS, DPYD, NME4 | POLB 110/4885P2RY2 401/4885P2RY4 374/4885 |
| US-20210101923-A1 | NUCLEIC ACID PRODRUGS | NUDT1, PNP, TYMP | POLB 82/4885P2RY2 212/4885P2RY4 179/4885 |
| US-20180346508-A1 | NUCLEIC ACID PRODRUGS | NUDT1, PNP, TYMP | POLB 82/4885P2RY2 212/4885P2RY4 179/4885 |
| US-10745435-B2 | Nucleic acid prodrugs | POLRMT, FPGS, POLN | POLB 11/4885P2RY2 1350/4885P2RY4 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.